Biosimilars Market is expected to Grow at the CAGR of 22.6% During 2015-2022

According to a recently published report, the Biosimilars Market is expected to grow at the CAGR of 22.6% during 2015-2022. The segmentation of global biosimilars market is based on product type, application, technology, services and geography. The report on Global Biosimilars Market Forecast, 2015-2022 (by product type, application, technology, services and geography) provides detailed overview and predictive analysis of the market.
Full report available Global Biosimilars Market Forecast, 2015-2022 (by product type, application, technology, services and geography) report at http://www.briskinsights.com/report/biosimilars-market
Increasing number of off patented drugs, rising pressure to decrease healthcare expenditure and cost effectiveness are the various factors that are driving the growth of global biosimilars market. Market players are implementing various growth strategies in the market to gain a competitive edge. New product launch, product pipelines, agreements and collaborations were certain major strategies adopted by players. Some of the challenges faced by biosimilars market are fledgling regulatory framework and various manufacturing related issues.
Scope of the report
1. Global Biosimilar market by product type, 2012 - 2022 ($ billion)
1.1. Recombinant Peptides
1.1.1. Glucagon
1.1.2. Calcitonin
1.2. Recombinant Glycosylated Proteins
1.2.1. Erythropoietin (EPO)
1.2.2. Follitropin
1.2.3. Monoclonal Antibodies (MABS)
1.3. Recombinant Non-Glycosylated Proteins
1.3.1. Interferons
1.3.2. Recombinant Human Growth Hormone (RHGH)
1.3.3. Granulocyte Colony-Stimulating Factor (Filgrastim)
1.3.4. Insulin
2. Global Biosimilar market by application type, 2012 - 2022 ($ billion)
2.1. Blood Disorders
2.2. Chronic and Autoimmune Diseases
2.3. Growth Hormone Deficiency
2.4. Infectious Diseases
2.5. Other Applications
3. Global Biosimilar market by technology, 2012 - 2022 ($ billion)
3.1. Nuclear magnetic resonance technology
3.2. Western blotting
3.3. Monoclonal antibodies technology
3.4. Electrophoresis
3.5. Chromatography
3.6. Bioassay
3.7. Recombinant DNA technology
3.8. Mass spectrometry
4. Global Biosimilar market by technology, 2012 - 2022 ($ billion)
4.1. Clinical trials
4.2. Contract research & manufacturing services (CRMS)
5. Global Biosimilar market , regional outlook, 2012-2022(in $billion)
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. Middle East & Africa
5.5. Latin America
6. Company profiles
6.1. Amgen
6.2. Biocon Ltd.
6.3. Celltrion, Inc.
6.4. Dr. Reddy's Laboratories
6.5. Hospira,inc
6.6. Merck KGAA
6.7. Mylan, Inc.
6.8. Roche Diagnostics
6.9. Sandoz International GmbH
6.10. Teva Pharmaceutical Industries Ltd.
6.11. Stada Arzneimittel AG
6.12. Ratiopharm GmbH
6.13. Intas Pharmaceuticals Ltd.
6.14. LG Life Sciences
6.15. Synthon Pharmaceuticals, Inc.
Request Sample: http://www.briskinsights.com/sample-request/136
About Us:
Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies. Our team of 200 analysts’ provides enterprises with strategic insights. Brisk Insights works to help enterprises grow through strategic insights and actionable solutions.
Contact Us:
Office 1094
109 Vernon House, Friar Lane
Nottingham
NG1 6DQ
United Kingdom
Ph. No. +448081890034
Email: sales@briskinsights.com
Company: http://www.briskinsights.com